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OBJECTIVE: The aim of this study is to determine clinical, pathological, and treatment-relevant variables associated with long-
term (90-month) overall survival in patients with lung metastases undergoing pulmonary metastasectomy. 
METHODS: A retrospective review was performed of patients who were admitted with lung metastases, and who underwent 
thoracotomy for resection, after treatment of a primary tumor. Data were collected regarding demographics, tumor features, treat-
ment, and outcome. 
RESULTS: Patients (n = 529) were submitted to a total of 776 thoracotomies. Median follow-up time across all patients was 21.6 
months (range: 0-192 months). The postoperative complication rate was 9.3%, and the 30-day mortality rate was 0.2%. The ninety-
month overall survival rate for all patients was 30.4%. Multivariate analysis identified the number of pulmonary nodules detected 
on preoperative CT-scan, the number of malignant nodules resected, and complete resection as the independent prognostic factors 
for overall survival. 
CONCLUSION: These results confirm that lung metastasectomy is a safe and potentially curative procedure for patients with 
treated primary tumors. A select group of patients can achieve long-term survival after resection.
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INTRODUCTION
The presence of metastases in patients with malignant 
tumors is a sign of advanced systemic disease1. 
Consequently, few patients survive more than one year after 
diagnosis.2 However, over 20% of patients with solid tumors, 
including colorectal adenocarcinoma, may have metastases 
exclusively in the pulmonary parenchyma, with no detectable 
involvement of other organs. In these patients, surgical 
resection of lung metastases may significantly impact long-
term survival.3 We have recently reported on metastatic lung 
cancer in Brazil4 and reviewed possible sources of new anti-
tumoral drugs from Brazilian plant extracts.5
Pulmonary metastasectomy is currently indicated 
for patients with the following criteria: primary tumor 
controlled; no evidence of metastases outside lung 
parenchyma; possibility of complete resection as verified 
by chest imaging; pulmonary function compatible with 
the proposed lung resection procedure; and lack of another 
available treatment that would be more effective than 
metastasectomy.6 Using these criteria for metastasectomy, 
several retrospective series have reported five-year survival 
rates ranging from 30% to 40%.7 
These results are encouraging considering that all of 
the patients included presented with metastatic disease. 
However, there is a clear need to refine these criteria to better 
identify patients who would benefit from surgical resection 
of lung metastases. More accurate criteria may eventually 
improve long-term survival rates and avoid unnecessary 
surgical procedures. In order to define the selection factors, 
many authors have reviewed their experience with lung 
metastasectomy in an effort to identify variables associated 
with better survival. The majority of these series included 
536
CLINICS 2009;64(6):535-41Surgical resection of lung metastases
Younes RN et al.
a limited number of patients treated over a long period of 
time, and the heterogeneity of the studied population did not 
allow for definitive conclusions. Today, complete surgical 
resection, long disease-free intervals, and a suitably low 
number of metastases are considered the most important 
variables associated with better survival rates.8 
Since the early 1990s, our institution has employed a 
continuous protocol-oriented approach to treat patients with 
resectable lung metastases. Our goal was to define factors 
related to outcome following lung metastasectomy in our 
patient population. All patients in the studied population 
underwent similar preoperative imaging, together with 
clinical and surgical evaluations. This was done to generate 
a more homogeneous and comparable group of patients, 
each of whom had detailed information registered in their 
individual records. 
The goal of this study is to evaluate outcomes following 
the surgical treatment of lung metastases in patients treated 
at a single institution, as well as to identify prognostic factors 
that may significantly impact long-term overall survival. Our 
results will allow us to more precisely define the subgroups 
of patients who may benefit from surgical therapy. 
METHODS
This is a retrospective analysis of patients previously 
diagnosed with primary malignant solid tumors and who 
subsequently underwent surgical resection of lung nodules 
in the context of suspected or diagnosed metastatic lesions. 
All patients were admitted and treated in the Department 
of Thoracic Surgery of AC Camargo Hospital from 1990 to 
2006. This study was approved by the ethics committee at 
our institution.
Data were collected from medical record reviews of 
individual patients. The following characteristics of the 
primary tumor were recorded: primary site, date of surgical 
resection, histological type, and adjuvant or neoadjuvant 
treatment associated with the resection. 
All patients were evaluated for lung nodules during the 
pretreatment evaluation and staging of a neoplasm or during 
routine follow-up after the treatment of various primary 
tumors. Disease-free interval was defined as the time 
period between the treatment of the primary tumor and the 
diagnosis of pulmonary metastases.
Patients were considered eligible for pulmonary 
metastasectomy if they presented with the following 
characteristics: 1) primary tumor controlled or controllable, 
2) nodules confined to the lung parenchyma, 3) nodules that 
were amenable to surgical resection, 4) pulmonary function 
and clinical condition that were compatible with the planned 
operation, 5) predictable remaining lung function after 
resection that would allow for adequate postoperative quality 
of life, and 6) non-availability of a more suitable treatment 
option for the metastases.
All patients underwent a chest CT scan in order to evaluate 
the resectability of their pulmonary nodules. Radiology 
reports were reviewed in each patient file, and the following 
characteristics were recorded: number of pulmonary nodules, 
size of the largest nodule, and laterality. The preoperative 
evaluation of the nodules was routinely performed by 
the radiologist and the surgeon. In cases of significant 
discrepancies between the number of nodules identified by 
the surgeon and by the radiologist, the evidence was discussed 
with a specialist. The number of nodules included in this 
retrospective study was the final number confirmed by the 
surgeon after complete preoperative evaluation.
In the case of bilateral nodules on admission, a staged 
thoracotomy was performed starting on the side with the 
lowest likelihood of a complete resection. Several factors 
determined which side to start with, including the number 
of nodules identified by chest CT, the anatomical position 
of one or more nodules relative to the pulmonary hilum, and 
the potential need for a more complex and extensive lung 
resection.
Patients were placed under general anesthesia with 
selective single lung ventilation. Surgical access to 
the thorax was performed by lateral thoracotomy even 
for patients with bilateral metastases. In all cases, we 
attempted to completely resect all lung nodules, preserving 
lung parenchyma by resecting the tumor with a small 
margin (5 mm to 10 mm). We did not routinely perform 
mediastinal lymph node dissection or sampling. In the 
presence of a single pulmonary nodule, frozen section 
analysis was mandatory. If histological evidence suggested 
a possible primary lung tumor, the patient underwent 
pulmonary lobectomy with radical mediastinal lymph-node 
dissection when possible. Lung nodules were identified 
individually according to the site of resection and sent for 
histopathological analysis. 
Date of surgery, type of resection (complete or 
incomplete), number of malignant and benign resected 
nodules, size of the largest nodule, and type of lung resection 
(wedge, segmentectomy, lobectomy or pneumonectomy) 
were registered according to the surgical report in individual 
patient records. 
Some patients received chemotherapy, based on the 
medical oncologist’s opinion, before or after a surgical 
resection of lung nodules. The type of treatment and 
radiological response (complete, partial, stable or progression 
of disease, as defined by RECIST9) were collected.
Patients were discharged from the hospital following 
chest tube removal. Postoperative complications included: 
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fever>38°C, bleeding, air leakage for more than three 
days, Intensive Care Unit stay for more than two 
days, cardiac complications (arrhythmia, ischemia, 
infarction), pulmonary atelectasis, embolism or respiratory 
failure, renal failure, neurological complications (coma, 
stroke, motor and sensitive dysfunctions), and infection 
(bacterioscopy or culture confirming the presence of a 
bacterial infection).
Beyond hospital discharge, patients were followed-up 
by clinical examination, with radiological evaluations (chest 
X-rays and CT scans) every three months during the first two 
years post-resection and every six months subsequently until 
the fifth year. Annual radiological follow-up was performed 
thereafter. Other ancillary tests were performed consistent 
with symptoms or clinical suspicion of recurrence in organs 
other than the lungs. We recorded recurrence when new 
lesions were identified in the lungs or in other organs. When 
necessary, we performed a histological confirmation of a 
new tumor. When recurrence was again limited to the lung 
parenchyma, and if the disease was considered resectable 
by the attending thoracic surgeon, the patient underwent 
additional metastasectomies as needed. 
After complete surgical resection, all patients were 
evaluated in the department of clinical oncology, and 
systemic treatment was administered by the clinical 
oncologist.
The characteristics of the patients included in this study 
are shown in Table 1.
Variables  n  %
Age (mean: 45.7 years, median: 50.1, range: 3.7-89.2 years)
Age subgroups (years)
0-12 n=38 7.2%
13-40 n=155 29.3%
65 n=231 43.7%
70 n=105 19.8%
Gender
Male (n=267) 50%
Female (n=262) 50%
Primary tumor site
Bone n=105 19.9%
Head-Neck n=101 19.2%
Soft tissue n=72 13.7%
Breast n=69 13.1%
Colorectal n=51 9.7%
Skin n=40 7.8%
Uterus n=18 3.4%
Kidney n=15 2.8%
Stomach n=8 1.5%
Bladder n=3 0.6%
Other n=44 8.4%
Histology of the primary tumor
Adenocarcinoma n=154 29.2%
Osteosarcoma n=86 16.3%
Squamous cell n=81 15.3%
Soft tissue sarcoma n=75 14.2%
Malignant melanoma n=48 9.1%
Other n=84 15.9%
Disease-free interval (months)
≤ 12 n=227 42.9%
>12 n=302 57.1%
Number of nodules on CT scan
≤ 2 n=301 56.9%
3-4 n=79 14.9%
>4 n=149 28.2%
Variables  n  %
Laterality of the nodules
Right lung n=185 35%
Left lung n=123 23.3%
Bilateral n=220 41.7%
Type of resection
Pneumonectomy n=3 0.6%
Lobectomy n=65 12.3%
Segmentectomy n=180 34%
Wedge resection n=260 49.1%
Biopsy n=20 3.8%
Number of resected nodules: median 1 (0-multiple)
Number of malignant nodules resected
<2 n=180 44.6%
2-4 n=164 40.6%
>4 n=60 14.8%
Number unknown n=125
Diameter of greater nodule
≤1 cm n=163 31%
1.1-3 cm n=256 48.7%
>3 cm n=107 20.3%
Number of thoracotomies
1 n=331 62.6%
2 n=134 25.3%
3 n=40 7.6%
>3 n=24 4.5%
Complete resection at last thoracotomy
Yes n=408 77.1%
No n=120 22.7%
Adjuvant chemotherapy after lung resection
No n=354 66.9%
Yes n=160 30.2%
Unknown n=15 2.8%
Table 1 - Patient characteristics
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Statistical Analyses
Continuous data are presented as medians, and 
categorical data are presented as percentages. Overall and 
disease-free survival rates were estimated using Kaplan-
Meier analysis10. Log-rank and Breslow analyses were used 
to compare differences between variables. Overall survival 
was estimated from the date of surgery to the date of last 
follow-up or until death from any cause. The influence 
of each variable on overall and disease-free survival was 
calculated. 
Multivariate analysis to determine the independent 
prognostic factors for overall survival was determined by 
the Cox proportional hazard model.11 Whenever more than 
one procedure was performed, survival time was determined, 
with time zero denoting the first thoracotomy.
Statistical analyses were performed using SPSS 11.5 for 
Windows. Significant differences were defined as p<0.05.
RESULTS 
The patients included in this retrospective study (n = 
529) underwent a total of 776 thoracotomies. The average 
follow-up time for all patients was 40 months, with a 
median of 21.6 months (range: 0-192 months), and eight 
patients (1.5%) were lost to follow up. Most patients were 
discharged by the fifth postoperative day (length of stay in 
hospital ranged from two days to 27 days, with a median of 
four days). The postoperative complication rate was 9.3% for 
the 776 thoracotomies. More than one complication occurred 
in some patients (infection n=19, atelectasis n=29, cardiac 
arrhythmia n=18, stroke n=2, myocardial infarction n=3, 
prolonged air leak n=28), and the 30-day mortality rate was 
0.2% (n=2, due to respiratory failure and stroke).
The ninety-month overall survival rate for all patients 
was 30.4% (Figure 1).
Figures 2-7 show the significant prognostic factors for 
overall survival, as identified by univariate analyses. 
All other factors evaluated in the univariate analyses, 
including type of resection, response to preoperative 
chemotherapy, number of resected nodules, and the total 
number of thoracotomies in an individual patient, were not 
statistically significant (p>0.05).
Multivariate analysis identified the number of pulmonary 
nodules (p<0.001), the number of malignant nodules 
resected (p=0.001), and complete resection (p<0.001) as the 
Figure 1 - Overall survival rates for all patients included
Figure 2 - Overall survival according to primary tumor histology
Figure 3 - Overall survival according to disease-free interval (DFI)
Figure 4 - Overall survival rates according to the number of nodules identi-
fied using CT Scans 
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are confined to the lungs. Therefore, resectability should 
be evaluated preoperatively with great care. The recent 
introduction of positron emission tomography using 18F- 
fluorodeoxyglucose (FDG PET-CT) has proven to be of 
clinical value for the proper staging of cancer patients. The 
use of this technology during the preoperative evaluation 
of candidates for lung metastasectomy has been shown to 
eliminate 21% of patients otherwise deemed resectable.15 
Unfortunately, our study population did not routinely 
undergo this imaging evaluation because the method was not 
available in our institution for most patients.
The 529 patients included in this study underwent 776 
thoracotomies for the treatment of lung metastases. The 
overall survival of patients at 90 months in our study was 
30.4%, with average follow-up of 40 months. Eight patients 
(1.5%) were lost to follow-up.
The histological type of a primary malignant tumor 
has been shown to influence the results of metastasectomy 
in previous studies.1 In this study, survival rates were 
significantly better for patients with adenocarcinoma. 
Multivariate analysis, however, did not identify this variable 
as an independent prognostic factor. Better systemic therapy 
for patients with metastatic colorectal adenocarcinoma might 
explain the apparently favorable long-term outcome. Our 
study failed to provide sufficient evidence to support this 
observation. 
On the basis of our univariate analysis, patients with 
synchronous metastases (DFI<12 months) exhibited 
significantly lower survival rates, compared to patients with 
metachronous disease, than reported in other studies.2,7 
On the other hand, this factor was not significant in our 
multivariate analysis. 
Several reports have demonstrated the prognostic 
importance of the number of nodules.7 The sensitivity 
of preoperative imaging examinations of pulmonary 
metastases varies depending on the technique used. Dellai 
Figure 5 - Overall survival according to nodule laterality
Figure 6 - Overall survival according to the number of resected malignant 
nodules
Figure 7 - Overall survival according to the type of surgical resection 
(complete or incomplete)
independent prognostic factors for overall survival (Table 
2).
DISCUSSION 
Thirty to 40% of all extrathoracic cancers lead to 
secondary pulmonary lesions during the course of the 
disease, and approximately 20% of these cases feature 
metastases that are confined to the lungs.2,7,12-14 Improved 
survival following resection of lung metastases has 
broadened the surgical indications for these lesions. It is 
likely that surgery itself impacts the outcome of patients 
who are candidates for a complete resection of nodules that 
Table 2 - Multivariate analysis for overall survival
Variables included in the model p
Primary tumor site 0.091
Histology of the primary tumor 0.086
Disease-free interval (months) 0.063
Number of nodules identified on the CT scan <0.001
Laterality of the nodules 0.131
Number of resected nodules 0.069
Number of malignant nodules resected 0.001
Diameter of greater nodule 0.319
Complete resection <0.001
Adjuvant chemotherapy after lung resection 0.772
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et al16 evaluated the precision of the diagnosis and the 
exact quantification of lung nodules using computerized 
tomography. All of the nodules were subsequently resected, 
revealing a diagnostic accuracy of 51%. In a prospective 
study involving 182 patients in Brazil, the CT scan identified 
the exact number of nodules resected in 47% of all cases. 
However, the CT scan underestimated the actual number 
of lung nodules found during surgery in 28% of cases and 
overestimated the number in 24%.2
A recently published study by Cerfolio et al 17 showed 
that in 37% of patients who were candidates for video-
assisted thoracic surgery (VATS), intraoperative palpation 
during a formal thoracotomy detected more nodules than had 
been identified using preoperative imaging (CT scans). VATS 
has a definitive role in the management of solitary pulmonary 
lesions that are suspected to be metastatic, but the use of 
thoracoscopic techniques for pulmonary metastasectomy is 
controversial because small metastatic foci may be missed 
without thorough finger palpation of the lung. Prospective 
studies are currently evaluating this issue in several centers.
In our study, the number of nodules exerted a significant 
impact on long-term overall survival using both univariate 
and multivariate analyses. Similar observations have been 
previously reported in other publications7,18
In most studies published to date, there has been no 
significant difference in survival of patients with metastases 
confined to one lung compared to bilateral lesions.19-22 
However, univariate analysis in this study suggested a 
significant difference in survival rates between patients 
presenting with unilateral or bilateral disease. However, this 
factor was found not to be significant under multivariate 
analysis.
Preoperative or postoperative systemic therapy had 
no significant impact on long-term survival rate in 
this patient population, consistent with data published 
elsewhere.3,7,8,23-26 
Complete resection was the most significant prognostic 
factor associated with long-term overall survival, both in 
univariate and multivariate analyses, as has been consistently 
reported elsewhere.27-35 The 90-month overall survival rate 
for patients who underwent complete resection in the context 
of metastatic disease was 35.1%, compared to 10.2% in the 
group who underwent incomplete resection.
Type of surgical resection and the total number of 
thoracotomies failed to influence the outcome of the patients, 
provided that complete resection was accomplished. Thus, 
we conclude that repeated resection may be beneficial in 
patients with relapses that are confined to the lung.36 As 
reported elsewhere, limited resection with lung parenchyma 
preservation is adequate to achieve clear margins and 
local control of the disease.8 Recently, alternative options 
like radiofrequency ablation have been evaluated for the 
management of lung metastases. Although promising, such 
methods are still considered experimental, since they are 
indicated only in limited numbers of patients, and they are 
usually considered clinically inappropriate for patients who 
can undergo a conventional resection.37 
CONCLUSIONS 
This study identified a group of patients who may 
benefit from pulmonary metastasectomy. Irrespective of 
other factors, all patients who present with fewer than four 
lung nodules should be considered candidates for surgical 
resection, after selection using the currently established 
inclusion criteria. Other patients should be individually 
evaluated in order to assess the impact of surgical resection 
on survival and long-term outcomes. Additional studies are 
needed to determine the role of adjuvant systemic therapy in 
patients stratified according to the histology of their primary 
tumors. 
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